A b s t r a c t
The detection of autoantibodies against nuclear antigens plays a central role in the diagnosis of systemic autoimmune rheumatic diseases (SARDs). The conventional autoimmune antibody testing strategy relies on the use of antinuclear antibody (ANA) testing by means of immunofluorescence (IF) as a sensitive initial screening procedure for SARDs, followed by a battery of extractable nuclear antigen (ENA) and double-stranded DNA assays. 1, 2 This sequential testing approach increases the overall diagnostic accuracy of the autoantibody immunoassays, because the use of more specific supplementary ENA and DNA assays counterbalances the pitfalls of ANA-IF with regard to its low specificity. 3 However, despite efforts of process automation, the current algorithms for performing multiple immune assays remain cumbersome and cost inefficient. An alternative semiautomated method has been advocated to replace ANA-IF using an integrated enzyme-linked immunosorbent assay (ELISA) testing system containing homogeneous nuclear substrates, which include antigens such as SSA/Ro (SS-A), SS-B/La (SS-B), nuclear ribonucleoprotein (RNP), Sm, Scl-70, and Jo-1 antigens for the detection of autoantibodies. 4, 5 Some commercial ENA ELISA assays also contain additional extracts from HEp-2 nuclei and nucleoli to identify antibodies directed at uncommon or not yet identified antigens present in the traditional ANA-IF test. However, published information in the medical literature reveals that there are variations in the performance characteristics of ENA immunoassays, particularly with ELISA testing systems. 6, 7 This is largely because of the Upon completion of this activity you will be able to:
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variations in choices and combinations of the commercial reagents, equipment, and the analytic cutoff values used by clinical laboratories. Recent advances in Luminex technology (Luminex, Austin, TX) offers a new method of rapid and cost-efficient detection of multiple ENA/DNA autoantibodies in a 1-step testing procedure. The diagnostic performance of multiplex bead-based immunoassay (MPBI) automated systems has been verified in several studies, [8] [9] [10] leading to its increased use by clinical laboratories to replace the historic ANA-IF-initiated diagnostic algorithms with the new automated screening systems. However, the American College of Rheumatology (ACR) recently issued a cautionary note regarding this change in technology. 11 The ACR position statement emphasized the fact that hospital and commercial laboratories using ELISA or MPBI platforms are to gather sufficient analytic information to ensure the diagnostic performance of the new analytic platforms, which are the same or better than traditional ANA-IF. This study evaluated 2 commercially available ENA immunoassay systems-a conventional ELISA method and a new MPBI method. The aim was to develop an appropriate analytic framework to assess the diagnostic performance of ENA immunoassays for both screening and diagnosis of SARDs. The new ENA immunoassays have the potential of releasing all ENA/DNA analytic information to the laboratory and clinical users. It is therefore important to understand the performance characteristics of ENA immunoassays, to meet both test-utility objectives and be an important and integral part of the technology assessment methodology.
Materials and Methods

Patients and Blood Specimens
This single-institution study identified patients who underwent testing for autoimmune antibodies at the Vancouver General Hospital Immunology Reference Laboratory (Vancouver, Canada) from December 2009 to August 2010. This study was approved by the University of British Columbia research ethics board and the hospital ethics review board. The clinical diagnoses of patients in the study were obtained through a review of clinical consultation notes, hospital discharge records, or a supplementary questionnaire sent to the attending physicians. Patients were separated into 3 categories based on the following clinical diagnoses: (1) SARDs category; (2) non-SARDs, immune category-patients with other forms of immunemediated diseases; (3) non-SARDs, non-immune categorypatients with no known SARDs or immune-mediated diseases ❚Table 1❚. In addition to the original diagnostic tests in the patient records, additional autoimmune assays were conducted using residual frozen serum samples stored at -70°C freezer in the immunology laboratory for a maximum period of 3 months. Patients were considered eligible for the study if there was clear documentation of the clinical diagnoses and sufficient specimens to complete the full panel of the autoimmune antibody tests evaluated in the study.
Specimens of the 329 patients who were eligible for the retrospective study were analyzed and linear discriminant analysis (LDA) models developed; the test data were considered as the training series. An additional 103 consecutive patient samples received at the immunology laboratory prospectively since August 2010 were used to validate the LDA models (validation series). 
Autoantibodies Assays
All assays were approved for clinical laboratory use and were performed according to the manufacturers' protocols. ANA-IF was performed on a 1:80 diluted serum sample using an immunofluorescence kit (Bio-Rad, Redmond, WA) containing HEp-2 cells as a substrate. Two ENA-based immunoassays were used as screening tests for SARDs. The first was an ELISA method (QUANTA Lite assay, INOVA Diagnostics, San Diego, CA), performed with the automated ELISA system (DSX Four-Plate Automated ELISA Processing System, Dynex Technologies, Chantilly, VA). The ELISA tests were used for the semiquantitative detection of 6 extractable nuclear antigens, including SS-A, SS-B, RNP, Scl-70, Sm and Jo-1 antigens, as well as dsDNA. These tests were deployed both as a screening test with the 6 ENA components combined into a single test (referred to as ENA6) 9 and as individual assays for each of the ENA/DNA components (referred to as ENA/ELISA or ENA-DNA/ELISA tests). The second assay was an MPBI (AthenNA Multi-Lyte ANA-II Plus test system, Zeus Scientific, Branchburg, NJ), performed using Luminex technology system. The AthenNA Multi-Lyte ANA-II Plus test system contains a suspension with separate distinguishable polystyrene beads that are conjugated with the following 9 ENA components: SS-A, SS-B, RNP, Scl-70, Sm, Jo-1, centromere, dsDNA, and histones. When used as a screening procedure, AthenNA Multi-Lyte is capable of generating a mathematically derived ANA value (dANA) based on a computing formula generated by the analysis software.
Statistics
Data analysis was carried out with SPSS statistical software version 19.0 (SPSS, IBM, Chicago, IL). Sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the evaluation of the screening test approaches. We measured the error rates using a bootstrapping technique for the estimated values (%) derived from the contingency tables. For categorical data, we used the McNemar test for pairwise comparison of the test results. Differences were considered significant at a 5% probability level. For evaluating the dANA (MPBI) and ENA6 (ELISA) assays as screening tests to differentiate patients with SARDs from those without SARDs, the data were analyzed by the area under the receiver operating characteristics curve (AUC) and 95% confidence interval (CI). The receiver operating characteristic curve (ROC) represents the relationship between sensitivity and specificity in reference to the range of experimental cutoff values measured with the numerical absorbance data generated by the immunoassays. A z test was performed to compare the statistical significance between the 2 AUCs.
LDA was used to study the diagnostic performance of the selected ENA/DNA components. For each SARDs type, a unique discriminant function was generated based on the following equation:
D(x) = C 1 x 1 + C 2 x 2 + … + C n x n + C 0 where D(x) indicates discriminant scores; C, discriminant coefficient (unstandardized); C 0 , the initial constant; x, lognumerical absorbance data of the ENA/DNA component; and n, the number of ENA/DNA component variables in the ELISA or MPBI. The discriminant scores were used to separate true disease from nondisease states. Each patient is classified as having the true disease state if D(x) is more than zero or having the nondisease state if the score is less than or equal to zero. Sensitivity, specificity, AUC, and 95% CI were created to evaluate the accuracy in classifying the disease vs nondisease states with each of the ENA variables. For evaluating the ENA/DNA test as a diagnostic test for SARDs, the full LDA (discriminant analysis) model for the MPBI method contained the aforementioned 9 ENA-DNA variables enlisted in the AthenNA Multi-Lyte ANA-II Plus test system (ENA-DNA/MPBI). The full LDA model for the ELISA tests included a selected panel of ENA-DNA/ELISA tests, which formed part of the routine diagnostic testing algorithm used in our laboratory. The ENA-DNA/ELISA test panel contained the same 6 ENA components as ENA6 plus DNA. A backward elimination analysis was used to determine the minimum set of key determinants of the discriminating power of both MPBI and ELISA assays (reduced LDA model). 12 The backward selection begins with all the independent variables in the LDA models. It then attempts to delete individual variables, starting with the least significant variable in a stepwise manner. With the removal of each variable, LDA is repeated and a z test is performed to compare the new AUC of the intermediary reduced models with the full model. This algorithm stops when the removal of additional variables results in significantly lowered AUC values between the full and reduced LDA models.
Results
Screening Tests for SARDs
When used as a 1-stage screening procedure for SARDs, MPBI (dANA) and ELISA (ENA6) immunoassays correctly identified SARDs in 98 of 118 and 108 of 118 patients with SARDs, respectively (sensitivity, 83.1% vs 91.5%; P = .024). The ANA-IF method correctly diagnosed 101 of 118 patients with SARDs (sensitivity, 85.6%; paired comparison with MPBI and ELISA methods, P = .647 and .190, respectively) ❚Figure 1❚. However, the specificity was significantly higher for both the MPBI and ELISA methods than for ANA-IF. One hundred twelve and 84 true-negative results were seen with the MPBI and ELISA methods, respectively, among all 211 non-SARDs patients (specificity, 53.1% vs 39.8%, respectively; P < .001). Only 51 true-negative results were identified with the ANA-IF method (specificity, 24.2%; paired comparison with MPBI and ELISA methods, P < .001). Both MPBI and ELISA methods outperformed ANA-IF in differentiating patients with SARDs from non-SARDs patients. The AUC values generated by the direct measurements of the numeric absorbance data for the MPBI (dANA) and ELISA (ENA6) methods matched well with the corresponding AUC values derived from the use of linear discriminant analysis (MPBI: AUC, 0.79 vs 0.81, respectively; P > .05; ENA/ELISA with the 6 ENA components tested individually: AUC, 0.81 vs 0.83, respectively; P > .05). This verifies that the performance of the ENA assay as a screening step is derived from the combined contribution of the individual assays.
Diagnostic Performance of MPBI and ELISA ENA Immunoassays for SARDs
According to the LDA model, a higher correct classification rate was obtained among patients with systemic lupus erythematosus (SLE) with the MPBI method than the ELISA method (59.4% ± 6% and 48.4% ± 7%, respectively; P = .285); the same is true for the correct classification of the non-SLE patients with SARDs (48.1% ± 8%, 38.9% ± 9%, respectively; P = .785) ❚Figure 2❚. The lowest correct classification rates were seen among non-SARDs immune patients with both methods (27.4% ± 8% and 25.3% ± 8%, respectively; P = .715).
The aim of the backward elimination analysis was to determine the minimum set of key determinants of the discriminating power of the MPBI and the ENA/DNA ELISA assays. For both the MPBI and ENA/DNA ELISA assays, noncritical ENA components can be eliminated from the full LDA model to establish a reduced LDA model for each type of SARDs without affecting the overall diagnostic performance of the testing panel ❚Figure 3❚ and ❚Table 2❚. The results of the analysis showed that the discriminating power of the models was determined by a unique combination of ENA/DNA components associated with the SARDs conditions and also by the immunoassay systems in use ( Figure  3) . For SLE, all except centromere were shown to be the critical variables with the MPBI method, whereas all except Jo-1 were discriminating variables with the ELISA method.
In contrast, very few critical ENA variables were primarily responsible for the discriminating capability of the immunoassays among non-SLE SARDs conditions. SS-A and SS-B were shown to be the critical determinants for the diagnosis of Sjögren syndrome with both immunoassays. Similarly, the only critical determinant for the diagnosis of dermatomyositis/polymyositis was Jo-1 with the ELISA method. This latter category likely represented a group of heterogeneous diseases, with shared clinical manifestations of inflammation of skeletal muscles; DNA and centromere, in addition to Jo-1, also contributed significantly to the discriminating power of the MPBI assay for this group of diseases. For the diagnosis
Critical ENA-DNA components included in the models Noncritical ENA-DNA components removable from the models Not applicable ❚Figure 3❚ List of key extractable nuclear antigen (ENA)/DNA components required to retain the discriminating power of the linear discriminant analysis (LDA) model for the diagnosis of systemic autoimmune rheumatic disease (SARD). A1, systemic lupus erythematosus; A2, Sjögren syndrome; A3, polymyositis/dermatomyositis; A4, scleroderma; A5, mixed connective tissue disease. For both the multiplex bead-based immunoassay (MPBI) and ENA/DNA assays, noncritical ENA components can be eliminated from the full LDA model to establish a reduced LDA model for each type of SARD conditions without affecting the overall diagnostic performance of the testing panel. of scleroderma, Scl-70 and centromere were shown to be the critical discriminants with the MPBI method, while Scl-70 was the sole critical discriminant with the ELISA method. For the diagnosis of mixed connective tissue disease, RNP was the critical determinant with the MPBI method, while Sm and RNP were the critical determinants with the ELISA method. Overall, paired comparisons between the diagnostic performances of the methods were not statistically significant in each of 5 SARDs subtypes (Table 2) . Retrospective data are considered the training set for the LDA model development. No statistically significant difference emerged when comparing the AUC values of the training and validation sets for the MPBI method ❚Figure 4❚ and the ENA/DNA ELISA method (data not shown).
Discussion
This study was designed to assess the performance of various autoantibody immunoassays in a tertiary hospital laboratory environment and to determine whether a meaningful relationship could be drawn between the characteristics of autoantibody test results and the clinical diagnoses of patients in the study. Autoantibody testing is a classic example of a complex laboratory investigation, which necessitates multistep testing, intricate diagnostic algorithms, and sophisticated clinical knowledge for proper test interpretation. Linear discriminant analysis was used to determine the correct disease classification based on the analysis of normalized continuous data generated by the immunofluorescence signals of ENA markers. Recent technology transformation with the MPBI has enabled an "information push" process, resulting in simultaneous delivery of ENA/DNA analytic data and screening information to diagnosticians and clinicians. Therefore, a discrete method of performance evaluation must be able to examine the contribution of individual ENA/DNA components to the overall diagnostic performance. To the best of our knowledge, pattern recognition and machine learning statistical methods, including LDA, to generate a multivariant predictive model for disease classification has not been widely deployed in the study of predictive performance of autoantibody testing on SARDs.
ANA-IF is frequently ordered by physicians as a diagnostic aid to rule out SARDs in patients with no overt clinical manifestations. In such low pretest probability clinical scenarios, the use of a screening test method with high sensitivity and optimal specificity is important to avoid unnecessary patient anxiety associated with positive test results of dubious clinical significance. Our study highlighted the fact that the use of more specific screening immunoassays with comparable sensitivity to ANA-IF could be used effectively in a tertiary hospital and reference laboratory environment with a high prevalence of non-SARDs immune diseases. ANA positivity is often seen in healthy individuals, and previous studies have shown increased prevalence among the elderly population and hospitalized patients. 13 When the clinical diagnoses were reviewed among the consecutive ANA-positive patients in the validation series, the vast majority did not have an underlying SARDs condition. High prevalence of non-SARDs diseases among ANA-positive patients have also been observed in other large-scale studies in large hospital and reference clinical laboratories. [14] [15] [16] This study has several limitations. First, it was performed in a single reference laboratory. Second, the sample size of the less common forms of non-SLE SARDs was relatively small; hence the strength of the mathematical models cannot be firmly substantiated. In addition, the clinical information for patients was gathered through a retroactive chart review/ physician questionnaire process, which mostly documented the working formulation of the clinical diagnoses by the attending or specialist physicians at the time of hospital discharge. This likely included a wide range of patients with concurrent comorbidities or therapies or inactive SARDs conditions, which could affect the final diagnostic validity of some results. Nonetheless, the design of the study was to measure the diagnostic usefulness of autoantibody tests in a large tertiary hospital environment and to assess the challenges facing performance evaluation with new technology changes. This mathematical model can also be applied to multicenter trials or patient registries. It is also important to point out that the ENA immunoassays evaluated in the study contained only purified ENA antigens but no extracts from statistical methods involving multivariate analysis provides an understanding of the discriminating power of individual ENA/ DNA components for the diagnosis of SARDs conditions, and most importantly, the compatibility of the ENA antigens in commercial reagents provided by different manufacturers. The methods presented herein can also be used to determine and validate the optimal test combinations in the process of developing new laboratory diagnostic algorithms for SARDs.
